
This VERTIS CV post hoc analysis assessed ertugliflozin’s effects on weight loss and cardiorenal outcomes by baseline BMI. Among 8246 adults with type 2 diabetes and cardiovascular disease, ertugliflozin led to significant weight reduction at 3 and 5 years. More participants achieved ≥5% and ≥10% weight loss with ertugliflozin versus placebo. No significant differences were observed in the effects on heart failure or kidney outcomes across BMI subgroups. Safety remained consistent with previous data.
Like
Save
Share